Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2012

Open Access 01-12-2012 | Primary research

Suppressive effects of liquid crystal compounds on the growth of U937 human leukemic monocyte lymphoma cells

Authors: Junya Ishikawa, Yuuka Takahashi, Masaharu Hazawa, Yukako Fukushi, Atsushi Yoshizawa, Ikuo Kashiwakura

Published in: Cancer Cell International | Issue 1/2012

Login to get access

Abstract

Background

The aim of this study was to evaluate the biological and pharmaceutical activities of 14 amphiphilic liquid-crystalline compounds (LCs), i.e, phenylpyrimidine derivatives possessing D-glucamine and cyanobiphenyl derivatives with a terminal hydroxyl unit.

Results

The cytotoxic properties of the LCs on the cell growth, cell cycle distribution, and cell signaling pathway of U937 human leukemic monocyte lymphoma cells were assessed by flow cytometry and western blot analysis. Some LCs showed cytostatic effects, suppressing cell growth via S-phase arrest and without apoptosis in U937 cells. To investigate the mechanisms of the LC-induced S-phase arrest, proteins relevant to cell cycle regulation were investigated by western blot analysis. The rate of LC-induced S-phase arrest was congruent with the decreased expression of MCM2, cyclin A, cyclin B, CDK2, phospho-CDK1 and Cdc25C. Observed changes in cell cycle distribution by LC treated might be caused by insufficient preparation for G2/M transition. Considering the structure of the LCs, the rod-like molecules displaying cytotoxicity against U937 cells possessed flexible spacers with no bulky polar group attached via the flexible spacer.

Conclusions

Our results revealed that some LCs showed cytotoxic properties against non-solid type tumor human leukemic cells via LC-induced S-phase arrest and decreasing expression of several cell cycle related proteins.
Appendix
Available only for authorised users
Literature
1.
Kuo PL, Hsu YL, Lin TC, Chang JK: Induction of cell cycle arrest and apoptosis in human non-small cell lung cancer A549 cells by casuarinin from the bark of Terminalia arjuna Linn. Anticancer Drugs. 2005, 16: 409-415. 10.1097/00001813-200504000-00007.CrossRefPubMed
2.
Abe A, Yamane M, Tomoda A: Prevention of growth of human lung carcinoma cells and induction of apoptosis by a novel phenoxazinone, 2-amino-4,4[alpha]-dihydro-4[alpha], 7-dimethyl-3H-phenoxazine-3-one. Anticancer Drugs. 2001, 12: 377-382. 10.1097/00001813-200104000-00011.CrossRefPubMed
3.
Tang N, Du G, Wang N, Liu C, Hang H, Liang W: Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin. J Natl Cancer Inst. 2007, 99: 1004-1015. 10.1093/jnci/djm027.CrossRefPubMed
4.
Cheng JH, Hung CF, Yang SC, Wang JP, Won SJ, Lin CN: Synthesis and cytotoxic, anti-inflammatory, and anti-oxidant activities of 2',5'-dialkoxylchalcones as cancer chemopreventive agents. Bioorg Med Chem. 2008, 16: 7270-7276. 10.1016/j.bmc.2008.06.031.CrossRefPubMed
5.
Goel A, Prasad AK, Parmar VS, Ghosh B, Saini N: 7, 8-Dihydroxy-4-methylcoumarin induces apoptosis of human lung adenocarcinoma cells by ROS-independent mitochondrial pathway through partial inhibition of ERK/MAPK signaling. FEBS Lett. 2007, 581: 2447-2454. 10.1016/j.febslet.2007.04.052.CrossRefPubMed
6.
Chou TC, Zhang X, Zhong ZY, Li Y, Feng L, Eng S, Myles DR, Johnson R, Wu N, Yin YI, Wilson RM, Danishefsky SJ: Therapeutic effect against human xenograft tumors in nude mice by the third generation microtubule stabilizing epothilones. Proc Natl Acad Sci USA. 2008, 35: 13157-13162.CrossRef
7.
Zhang JH, Fan CD, Zhao BX, Shin DS, Dong WL, Xie YS, Miao JY: Synthesis and preliminary biological evaluation of novel pyrazolo[1,5-a] pyrazin-4(5H)-one derivatives aspotential agents against A549 lung cancer cells. Bioorg Med Chem. 2008, 16: 10165-10171. 10.1016/j.bmc.2008.10.066.CrossRefPubMed
8.
Takahashi Y, Hazawa M, Takahashi K, Nishizawa A, Yoshizawa A, Kashiwakura I: Suppressive effects of liquid crystal compounds on the growth of the A549 human lung cancer cell line. Invest New Drugs. 2010, 29: 659-665.CrossRefPubMed
9.
Ysoshizawa A, Takahashi Y, Nishizawa A, Takeuchi K, Sagishita M, Takahashi K, Hazawa M, Kashiwakura I: Biological activity of some cyanobiphenyl derivatives. Chem Lett. 2009, 38: 530-531. 10.1246/cl.2009.530.CrossRef
10.
Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C: A novel assay for apoptosis Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labeled Annexin V. J Immunol Methods. 1995, 184: 39-51. 10.1016/0022-1759(95)00072-I.CrossRefPubMed
11.
Hazawa M, Takahashi K, Wada K, Kawahara N, Kashiwakura I: Structure-activity relationships between the Aconitum C20-diterpenoid alkaloid derivatives and the growth suppressive activities of non-Hodgkin's lymphoma Raji cells and human hematopoietic stem/progenitor cells. Invest New Drugs. 2011, 29: 1-8. 10.1007/s10637-009-9327-4.CrossRefPubMed
12.
Lundberg AS, Weinberg RA: Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol. 1998, 18: 753-761.PubMedCentralCrossRefPubMed
13.
Ewen ME: Where the cell cycle and histones meet. Genes Dev. 2000, 14: 2265-2270. 10.1101/gad.842100.CrossRefPubMed
14.
Treisman JE, Follette PJ, O'Farrell PH, Rubin GM: Cell proliferation and DNA replication defects in a Drosophila MCM2 mutant. Genes Dev. 1995, 9: 1709-1715. 10.1101/gad.9.14.1709.CrossRefPubMed
15.
Todorov IT, Pepperkok R, Philipova RN, Kearsey SE, Ansorge W, Werner D: A human nuclear protein with sequence homology to a family of early S phase proteins is required for entry into S phase and for cell division. J Cell Sci. 1994, 107: 253-265.PubMed
16.
Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G: Cyclin A is required at two points in the human cell cycle. EMBO J. 1992, 11: 961-971.PubMedCentralPubMed
17.
18.
Norbury C, Blow J, Nurse P: Regulatory phosphorylation of the p34cdc2 protein kinase in vertebrates. EMBO J. 1991, 10: 3321-3329.PubMedCentralPubMed
19.
Zhang C, Fan X, Xu X, Yang X, Wang X, Liang HP: Evodiamine induces caspase-dependent apoptosis and S phase arrest in human colon lovo cells. Anticancer Drugs. 2010, 21: 766-776. 10.1097/CAD.0b013e32833d26a9.CrossRefPubMed
20.
Giard DJ, Aaronson SA, Todaro GJ, Amstein P, Kersey JH, Dosik H, Parks WP: In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst. 1973, 51: 1417-1423.PubMed
21.
Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, Ishikawa F, Takaku F, Yazaki Y, Hirai H: Frequent mutations in the p53 gene in human myeloid leukemia cell lines. Blood. 1992, 79: 2378-2383.PubMed
22.
O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ, Kohn KW: Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997, 57: 4285-4300.PubMed
23.
Takahashi Y, Hazawa M, Takahashi K, Sagisaka M, Kashiwakura I, Yoshizawa A: Supramolecular assembly composed of different mesogenic compounds possessing a w-hydroxyalkyl unit exhibits suppressive effects on the A549 human lung cancer cell line. Med Chem Comm. 2011, 2: 55-59. 10.1039/c0md00126k.CrossRef
24.
Hosseinimehr JS, Inanami O, Hamasu T, Takahashi M, Kashiwakura I, Asanuma T, Kuwabara M: Activation of c-kit by stem cell factor induces radioresistance to apoptosis through ERK-dependent expression of survivin in HL60 cells. J Radiat Res. 2004, 45: 557-561. 10.1269/jrr.45.557.CrossRef
Metadata
Title
Suppressive effects of liquid crystal compounds on the growth of U937 human leukemic monocyte lymphoma cells
Authors
Junya Ishikawa
Yuuka Takahashi
Masaharu Hazawa
Yukako Fukushi
Atsushi Yoshizawa
Ikuo Kashiwakura
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2012
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-12-3

Other articles of this Issue 1/2012

Cancer Cell International 1/2012 Go to the issue

Primary research

Cellular damage and apoptosis along with changes in NF-kappa B expression were induced with contrast agent enhanced ultrasound in gastric cancer cells and hepatoma cells

Primary research

Anticonvulsant and analgesic activities of crude extract and its fractions of the defensive secretion from the Mediterranean sponge, Spongia officinalis

Primary research

The characteristics of bone marrow-derived endothelial progenitor cells and their effect on glioma

Primary research

Cycloartane-3,24,25-triol inhibits MRCKα kinase and demonstrates promising anti prostate cancer activity in vitro

Primary research

Establishment and characterization of two human breast carcinoma cell lines by spontaneous immortalization: Discordance between Estrogen, Progesterone and HER2/neu receptors of breast carcinoma tissues with derived cell lines

Primary research

Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits